Barceló Carla, Sisó Pol, Maiques Oscar, de la Rosa Inés, Martí Rosa M, Macià Anna
Oncologic Pathology Group, University of Lleida, IRBLleida, 25198 Lleida, Spain.
Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Cancers (Basel). 2020 Feb 8;12(2):391. doi: 10.3390/cancers12020391.
T-type calcium channels (TTCCs) are overexpressed in several cancers. In this review, we summarize the recent advances and new insights into TTCC biology, tumor progression, and prognosis biomarker and therapeutic potential in the melanoma field. We describe a novel correlation between the Cav3.1 isoform and the increased basal autophagy in BRAF-mutant melanomas and after acquired resistance to BRAF inhibitors. Indeed, TTCC blockers reduce melanoma cell viability and migration/invasion in vitro and tumor growth in mice xenografts in both BRAF-inhibitor-sensitive and -resistant scenarios. These studies open a new, promising therapeutic approach for disseminated melanoma and improved treatment in BRAFi relapsed melanomas, but further validation and clinical trials are needed for it to become a real therapeutic option.
T型钙通道（TTCCs）在多种癌症中过度表达。在本综述中，我们总结了TTCC生物学、肿瘤进展、预后生物标志物以及在黑色素瘤领域的治疗潜力方面的最新进展和新见解。我们描述了Cav3.1亚型与BRAF突变型黑色素瘤以及获得性BRAF抑制剂耐药后基础自噬增加之间的新型关联。事实上，在BRAF抑制剂敏感和耐药的情况下，TTCC阻滞剂均可降低黑色素瘤细胞的活力以及体外迁移/侵袭能力，并抑制小鼠异种移植瘤的生长。这些研究为播散性黑色素瘤开辟了一种新的、有前景的治疗方法，并改善了BRAFi复发黑色素瘤的治疗，但要使其成为真正的治疗选择还需要进一步验证和开展临床试验。
